Skip to research
Margin Monkey THEMARGINMONKEY Start my free trialTry free

Mimedx Group (MDXG) stock in plain English

Free brief · no signupStart here
MDXGPublished Nov 19, 2026
Mimedx Group Inc
Healthcare · Biotechnology
Manufactures and sells human amniotic tissue allografts to treat chronic wounds and surgical incisions.
Assets:
Marietta processing siteCentralized tissue processing and corporate facility in Georgia
EpiFix product familyDehydrated amniotic membrane grafts for non-healing chronic wounds
Purion technologyPatented platform for sterilizing and preserving placental tissue matrices
Locked assetIn the full report
Rated Nov 19, 2026

Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.

69
OPS ScoreOperating finances
Latest quote
-2.20%$3.11
$453.83M
n/a (loss)
$304.58M

Change shown by the quote provider. Data may be delayed.

Financial statements, in plain wordsSales, profit, debt and cash, year by year
Published Nov 19, 2026Quotes updated Nov 20, 04:00 UTCOPS Score, TMM Score and the rating are research summaries, not advice or forecasts.
That was MDXG. The desk has 1,900+ more companies.Each one comes with its scores, its flags and the sources behind them.
7 days free · No card

What does Mimedx Group (MDXG) do?

Mimedx Group Inc (MDXG) is a U.S.-listed company in Healthcare (Biotechnology). What it does: Manufactures and sells human amniotic tissue allografts to treat chronic wounds and surgical incisions. It processes donated human placental tissue into biological grafts for wound care and surgical recovery. It is worth $453.83M on the market and sold $304.58M over the last year.

Market cap
$453.83M
P/E ratio
None (reported a loss)
Annual sales
$304.58M
Sector
Healthcare
Industry
Biotechnology
Brief updated
Nov 19, 2026

Brands and businesses behind MDXG

  • EpiFix: It is a dehydrated amniotic membrane graft that generates sales by helping heal diabetic foot ulcers and chronic wounds.
  • Epicord: It is a dehydrated umbilical cord allograft sold to wound centers to heal deep and hard to close wounds.
  • AmnioFix: It is an amniotic membrane allograft sold to surgical centers to reduce inflammation and scar formation.
  • AxioFill: It is a placental extracellular matrix particulate sold for packing deep and irregular surgical defects.

MDXG’s flags, in plain English

Each flag is a number from Mimedx Group’s reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 19, 2026.

Stupid Cash

Can pay this year's bills 4.4 times over. Cash in the bank covers a long stretch of running costs. The company can fund itself without borrowing or selling new shares.

Low debt

Low debt, only 0% of shareholder equity. The company owes very little compared with what it earns, so a bad year is less likely to force its hand.

Wide Gross Margin

Gross margin of 77% after the cost of making its products. There is a large gap between what its products cost to make and what they sell for, and that gap pays for everything else.

Burning Cash

Losing money, profit margin of -6.3%. The business spends more cash than it brings in. It has to cover the gap with cash on hand, new loans or new shares.

2 more green flags and 1 more risk note open with the free trial. Try it free for 7 days.

Questions about MDXG

How big is Mimedx Group?

Mimedx Group’s market cap is $453.83M: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $304.58M: what customers paid the company over the last year, before any costs.

What is MDXG’s P/E ratio?

MDXG has no P/E ratio right now. The company reported a loss, so there is no yearly profit to price.

What could go wrong with MDXG?

Medicare and private insurers frequently revise reimbursement coverage policies for skin substitutes, directly affecting customer purchasing volumes. That is one risk on Mimedx Group’s card. Its first risk flag is Burning Cash, explained above. The card holds 1 more risk note for trial accounts. A flag reads what the company reported. It does not predict the price.

Where do these numbers come from?

From Mimedx Group’s own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. MDXG’s filings on SEC.gov. The Margin Monkey is research, not advice.

Your first 7 days are free.Search all 1,900+ companies and open every card. Members also get the ratings, Picks and the TMM Score.
7 days free · No card